Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05765344 · ClinicalTrials.gov registry record · Phase 1
Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function
A Phase 1 study of Healthy and Hepatic Impairment, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
- 6
- Study locations
NCT05765344 is a Phase 1 study of Healthy and Hepatic Impairment that has completed, run by Gilead Sciences. The registered enrollment target is 74 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (89% lower). The trial reports 6 study locations across 3 states.
The verdict
NCT05765344, a Phase 1 study of Healthy and Hepatic Impairment, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goals of this study are to measure the amount of bulevirtide (BLV) that gets into the blood stream and how long it takes to get rid of it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal and impaired hepatic (liver) function.
Conditions Studied
Interventions
- DRUG Bulevirtide
Study Locations (6)
Florida
- Clinical Pharmacology of Miami, LLC - Miami
- University of Miami - Miami
- Orlando Clinical Research Center - Orlando
Texas
- Texas Liver Institute - San Antonio
- Pinnacle Clinical Research LLC - San Antonio
California
- Orange County Research Center - Lake Forest
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2025-01-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05765344
The ClinicalTrials.gov registry entry for NCT05765344 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (89% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Bulevirtide is the first listed.
NCT05765344 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Florida, Texas, California.
Frequently Asked Questions
What is clinical trial NCT05765344 about?
NCT05765344 is a clinical study titled "Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function". The goals of this study are to measure the amount of bulevirtide (BLV) that gets into the blood stream and how long it takes to get rid of it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal and impaired hepatic (...
What is the current status of trial NCT05765344?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2023-03-15. Estimated completion is 2025-01-13.
What conditions does trial NCT05765344 study?
This clinical trial studies the following conditions: Healthy, Hepatic Impairment.
What interventions are being tested in trial NCT05765344?
The interventions under investigation include: Bulevirtide (DRUG).
Who is sponsoring clinical trial NCT05765344?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05765344 being conducted?
This trial has 6 study locations across California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.